VAXON Biotech is a private company that was founded in 2004 and based in Paris-France. The company develops innovative therapeutic vaccines for the treatment of cancer including lung, prostate, breast, renal, liver and colorectal cancer, using its proprietary technology of optimized cryptic peptides.

Vaxon Biotech's vaccines are intended to treat existing cancers (therapeutic vaccines) by stimulating the immune system to recognize and attack human cancer cells without harming normal cells. These vaccines target antigens, overexpressed in tumor cells while present in very low quantities in normal cells.

VAXON has a pipeline of tumor vaccines which cover major HLA-I to treat most cancer patients. The most advanced vaccine Vx-001, has completed a "proof of principle" Phase I/II clinical trial. Vx-001 has shown good tolerance and elicits a strong immune response in most individuals, with a very significant clinical activity in patients with advanced cancers, especially Non Small Cell Lung Cancer (NSCLC), breast cancer and HepatoCellular Cancer (HCC). Vx-001 is due to start randomized, multicenter (Europe, US and Asia) pivotal phase III study in NSCLC in Q3 2009, aiming a marketing autorization in 2013.
Vx-001 has obtained an orphan drug designation for NSCLC from EMEA (European Medicines Agency) in November 2007. Vx-001 development plan and more particularly the phase III clinical trial, was approved by of EMEA (protocol assistance process, October 2008).